NCI: Fezolinetant Phase II Trial in Breast Cancer Survivors (NCI-2025-09480)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: National Cancer Institute, National Institutes of Health · Published: September 4, 2026 · Accessed: September 4, 2026

Visit the source ↗

Claims this source supports

• An NCI-listed phase II randomized, double-blinded, placebo-controlled trial is testing fezolinetant 45 mg daily versus placebo for moderate-to-severe vasomotor symptoms in breast cancer survivors on endocrine therapy (tamoxifen or aromatase inhibitors).
• Endocrine therapy commonly causes vasomotor symptoms, and these symptoms are a frequent reason women discontinue it; improving symptom control is a stated goal of the trial.